Bobak Azamian

CEO at Tarsus Pharmaceuticals

Bobby has served as President and CEO of Tarsus Pharmaceuticals since co-founding the company in 2017. In that time, Tarsus has established a leading team and culture, and completed successful fundraising efforts through an IPO and global partnerships. Tarsus continues to advance its pipeline into clinical studies, including its lead product, TP-03, which is now in Phase 3 clinical trials and commercial planning.

Bobby has co-founded and led two other novel therapeutics companies. Vibrato Medical, where he serves as Co-Chair, is developing a wearable treatment for peripheral arterial diseases, and has obtained NIH grant awards and Series A financing. Metavention, where he served as President and CMO through multiple clinical trials and Series A through C financings, is developing an interventional treatment for metabolic diseases.

Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer in numerous life sciences companies. He also served on the board of the nonprofit organization Octane.

Bobby trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Heath Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications. He enjoys sports, travel, and the arts, and spending time in Newport Beach with his wife, dog, and extended family.

Links

Previous companies

Third Rock Ventures logo
Versant Ventures logo
Metavention logo
Amgen logo

Timeline

  • CEO

    Current role

View in org chart